Vanita R Aroda1. 1. MedStar Health Research Institute, Hyattsville, Maryland.
Abstract
AIMS: To review the evolution and advancement of GLP-1 receptor agonist (GLP-1RA) therapy, through the lens of randomised controlled trials, from differentiating characteristics, efficacy, safety, tolerability, and cardiovascular outcomes, to evidence gaps and next steps. METHODS: Clinical review of published phase 3 or later RCT data studying efficacy, safety, and outcomes of approved GLP-1 RA therapies. RESULTS: Through a wealth of studies, including both placebo-controlled and active-controlled studies, GLP-1 RAs have demonstrated high glycemic efficacy and ability to facilitate weight loss, with minimal risk of hypoglycemia, potential to restore beta cell function, and evidence for improved cardiovascular outcomes in those at risk. CONCLUSIONS: Over a decade of clinical studies have established the unique contributions of GLP-1 RAs in the treatment of diabetes. Individual differences between the different GLP-1 RAs, in delivery, pharmacokinetic and clinical effects, exist, allowing for tailored approaches to clinical care. The strength of evidence generated through RCTs, both short-term and long-term studies, will continue to evolve and inform our current paradigms in diabetes care.
AIMS: To review the evolution and advancement of GLP-1 receptor agonist (GLP-1RA) therapy, through the lens of randomised controlled trials, from differentiating characteristics, efficacy, safety, tolerability, and cardiovascular outcomes, to evidence gaps and next steps. METHODS: Clinical review of published phase 3 or later RCT data studying efficacy, safety, and outcomes of approved GLP-1 RA therapies. RESULTS: Through a wealth of studies, including both placebo-controlled and active-controlled studies, GLP-1 RAs have demonstrated high glycemic efficacy and ability to facilitate weight loss, with minimal risk of hypoglycemia, potential to restore beta cell function, and evidence for improved cardiovascular outcomes in those at risk. CONCLUSIONS: Over a decade of clinical studies have established the unique contributions of GLP-1 RAs in the treatment of diabetes. Individual differences between the different GLP-1 RAs, in delivery, pharmacokinetic and clinical effects, exist, allowing for tailored approaches to clinical care. The strength of evidence generated through RCTs, both short-term and long-term studies, will continue to evolve and inform our current paradigms in diabetes care.
Authors: Richard A Manfready; Christopher B Forsyth; Robin M Voigt; Deborah A Hall; Christopher G Goetz; Ali Keshavarzian Journal: Curr Neurol Neurosci Rep Date: 2022-05-28 Impact factor: 5.081
Authors: Hale Yapici-Eser; Vivek Appadurai; Candan Yasemin Eren; Dilek Yazici; Chia-Yen Chen; Dost Öngür; Diego A Pizzagalli; Thomas Werge; Mei-Hua Hall Journal: Acta Neuropsychiatr Date: 2020-03-26 Impact factor: 3.403
Authors: Meena Jain; Glenn Carlson; William Cook; Linda Morrow; Marcella Petrone; Nicholas E White; Tao Wang; Jacqueline Naylor; Philip Ambery; Charles Lee; Boaz Hirshberg Journal: Diabetologia Date: 2018-12-28 Impact factor: 10.122
Authors: Angeles Vinuesa; Carlos Pomilio; Amal Gregosa; Melisa Bentivegna; Jessica Presa; Melina Bellotto; Flavia Saravia; Juan Beauquis Journal: Front Neurosci Date: 2021-04-23 Impact factor: 4.677